CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
dapsone geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02959970
NCT02959970Phase 4Completed
CompareCT.gov

An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Almirall, S.A.·interventional·Posted Nov 9, 2016·Updated Mar 3, 2020

In Brief

A Phase 4 clinical trial evaluating dapsone gel for Acne Vulgaris. Completed, enrolled 100 participants across 20 sites.

Detailed Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
CollaboratorsAllergan

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 9, 2016
Enrollment StartOct 31, 2016
Primary CompletionMar 9, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.6 years ago

Interventions

dapsone geldrug

Dapsone (ACZONE) 7.5% gel topically once daily.